AI Article Synopsis
- A hospital-based case-control study involving 629 ESCC patients and 686 cancer-free controls was conducted to examine the association between the CCND1 A870G polymorphism and esophageal squamous cell carcinoma (ESCC) in a Chinese Han population.
- Despite the study, no significant differences in allele frequencies or genotype distributions were found between cases and controls.
- A subsequent meta-analysis, including data from seven studies with a total of 2080 ESCC cases and 2833 controls, confirmed that the CCND1 A870G polymorphism is not associated with an increased risk of ESCC, even across different ethnicities.
Article Abstract
Studies examining the association between the cyclin D1 (CCND1) A870G (rs9344 G>A) polymorphism and esophageal squamous cell carcinoma (ESCC) have yielded inconsistent results. Here, we conducted a hospital-based case-control study in a Chinese Han population to assess the association between the CCND1 A870G polymorphism and ESCC. We then performed a meta-analysis to further investigate this association. We recruited 629 patients with ESCC and 686 cancer-free controls. Genotyping was performed with the polymerase chain reaction-ligase detection reactions (PCR-LDR) method. The meta-analysis was performed with the STATA 12.0 software. The case-control study showed no significant difference between the ESCC cases and controls in the allele frequencies or genotype distributions of the CCND1 A870G polymorphism. To obtain a more precise estimate of this relationship, we performed a meta-analysis of seven case-control studies involving a total of 2080 ESCC cases and 2833 controls. The meta-analysis suggested that the CCND1 A870G polymorphism is not associated with a risk of ESCC. A further subgroup analysis based on ethnicity also detected no association. This study suggests that the CCND1 A870G polymorphism is not associated with the risk of ESCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612867 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Epidermal Growth Factor Receptor (EGFR) and SMAD4 negatively correlated in the progression of gallbladder cancer in Eastern Indian patients.
BMC Gastroenterol
December 2024
Human Genetics Unit, Indian Statistical Institute, 203, B. T. Road, Kolkata, 700108, India.
Background And Introduction: Two and half percent of the Indian population suffer from gallbladder cancer (GBC). The primary factors that lead GBC are associated with mutation of several protooncogenes such as EGFR, ERBB2, Myc, and CCND1 along with dysregulation of several tumor suppressor genes such as SMAD4 and CDKN2A. Bacterial infection caused by S.
View Article and Find Full Text PDFG870A Polymorphic Variants of Gene and Cyclin D1 Protein Expression as Prognostic Markers in Laryngeal Lesions.
Diagnostics (Basel)
April 2022
Department of Otolaryngology, Head and Neck Oncology, Medical University of Lodz, 90-153 Lodz, Poland.
CCND1 gene encodes Cyclin D1 protein, the alternations and overexpression of which are commonly observed in human cancers. Cyclin D1 controls G1-S transition in the cell cycle. The aim of the study was to assess utility of the genotyping and protein expression in predicting the susceptibility of transformation from normal tissue to precancerous laryngeal lesions (PLLs) and finally to laryngeal cancer (LC).
View Article and Find Full Text PDFSingle Nucleotide Polymorphism (A870G) of the gene: association with colorectal cancer susceptibility.
Gastroenterol Hepatol Bed Bench
January 2017
Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Aim: The aim of this study is to demonstrate the role of gene polymorphism, A870G, in susceptibility to sporadic colorectal cancer in Iranian population.
Background: It has been distinguished that gene is one of the main genes in Wnt signaling pathway which involves in generating colorectal cancer. Nonetheless, there is no consistent result in terms of association between the genetic variations of this gene and colorectal cancer risk.
ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
Pharmacol Res
June 2016
Pharmacogenetics Unit, UGC Provincial de Farmacia de Granada, Instituto de Investigación Biosanitaria de Granada, Complejo Hospitalario Universitario de Granada, Avda., Fuerzas Armadas, 2, Spain. Electronic address:
HER2-positive breast cancer patients treated with trastuzumab schemes have good initial clinical outcomes. Despite this beneficial effect, many patients experiment resistance to these drugs. Several gene polymorphisms in ABCB1, HER2, and CCND1 have been proposed as potential predictors of clinical outcomes of trastuzumab schemes.
View Article and Find Full Text PDFLack of association between cyclin D1 A870G (rs9344) polymorphism and esophageal squamous cell carcinoma risk: case-control study and meta-analysis.
Int J Clin Exp Med
November 2015
Department of Cardiothoracic Surgery, Affiliated People's Hospital of Jiangsu University Zhenjiang, China.
Article Synopsis
- A hospital-based case-control study involving 629 ESCC patients and 686 cancer-free controls was conducted to examine the association between the CCND1 A870G polymorphism and esophageal squamous cell carcinoma (ESCC) in a Chinese Han population.
- Despite the study, no significant differences in allele frequencies or genotype distributions were found between cases and controls.
- A subsequent meta-analysis, including data from seven studies with a total of 2080 ESCC cases and 2833 controls, confirmed that the CCND1 A870G polymorphism is not associated with an increased risk of ESCC, even across different ethnicities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!